Tacita Capital’s AbbVie ABBV Stock Holding History

Tacita Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.9K	Hold	165	–	–	0.02%	152
2025 Q4	$37.7K	Sell	165 -33	-17%	-$7.52K	0.02%	156
2025 Q3	$45.8K	Hold	198	–	–	0.03%	147
2025 Q2	$36.8K	Hold	198	–	–	0.02%	159
2025 Q1	$41.5K	Hold	198	–	–	0.03%	142
2024 Q4	$35.2K	Sell	198 -150	-43%	-$27.6K	0.03%	149
2024 Q3	$68.7K	Hold	348	–	–	0.04%	130
2024 Q2	$59.7K	Hold	348	–	–	0.04%	138
2024 Q1	$63.4K	Buy	348 +63	+22%	+$10.9K	0.04%	135
2023 Q4	$44.2K	Sell	285 -225	-44%	-$32.8K	0.03%	152
2023 Q3	$76K	Hold	510	–	–	0.06%	116
2023 Q2	$69K	Hold	510	–	–	0.05%	116
2023 Q1	$81K	Buy	510 +100	+24%	+$15.3K	0.06%	100
2022 Q4	$66K	Hold	410	–	–	0.05%	106
2022 Q3	$55K	Sell	410 -125	-23%	-$17.9K	0.04%	109
2022 Q2	$82K	Hold	535	–	–	0.06%	107
2022 Q1	$87K	Hold	535	–	–	0.05%	109
2021 Q4	$72K	Hold	535	–	–	0.04%	115
2021 Q3	$58K	Sell	535 -300	-36%	-$34.3K	0.04%	123
2021 Q2	$94K	Hold	835	–	–	0.06%	109
2021 Q1	$90K	Buy	835 +125	+18%	+$13.4K	0.06%	117
2020 Q4	$76K	Buy	+710	New	+$68.2K	0.05%	118

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tacita Capital's ABBV Position: Q1 2026 in Review

Tacita Capital held its AbbVie (ABBV) position steady in Q1 2026 at 165 shares worth $35.9K. The position accounts for 0.02% of the portfolio, ranked #152.

Tacita Capital first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $94K in Q2 2021. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Tacita Capital held 165 shares of AbbVie worth $35.9K as of Q1 2026.
Tacita Capital left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.02% of Tacita Capital's portfolio in Q1 2026, its #152 holding.
Tacita Capital first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
Tacita Capital's AbbVie position peaked at $94K in Q2 2021.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Tacita Capital's 13F filing for Q1 2026, filed 7 May 2026.